Head-To-Head Comparison: Osiris Therapeutics (OTCMKTS:OSIR) vs. Protalix BioTherapeutics (NYSE:PLX)

Osiris Therapeutics (OTCMKTS:OSIR) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Valuation & Earnings

This table compares Osiris Therapeutics and Protalix BioTherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A
Protalix BioTherapeutics	$61.95 million	3.06	$8.31 million	$0.07	34.00

Protalix BioTherapeutics has higher revenue and earnings than Osiris Therapeutics.

Profitability

This table compares Osiris Therapeutics and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Osiris Therapeutics	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Insider and Institutional Ownership

0.3% of Osiris Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 43.4% of Osiris Therapeutics shares are owned by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Osiris Therapeutics and Protalix BioTherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Osiris Therapeutics	0	0	0	0	0.00
Protalix BioTherapeutics	0	0	1	0	3.00

Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 530.25%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Osiris Therapeutics.

Summary

Protalix BioTherapeutics beats Osiris Therapeutics on 5 of the 9 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.